BioSpace News Archive

Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein.

Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that The Lancet Gastroenterology & Hepatology published the results of the pivotal PEDFIC 1 trial, which evaluated Bylvay® (odevixibat) for the treatment of progressive familial intrahepatic cholestasis (PFIC).

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life-changing radiopharmaceuticals, will participate in the following upcoming investor conferences.

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, announces that the first clinical site has now been fully opened for its clinical study to evaluate QRX003 for the treatment of the rare genetic disease, Netherton Syndrome.

SciSparc Ltd. announced its board of directors authorized the Company to take actions to implement a $1 million buyback program for the Company’s ordinary shares, no par value.

Vanderbilt University Medical Center (VUMC) and Roivant Social Ventures (RSV) announced an intention to collaborate in developing therapies for traditionally underserved populations and diseases.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced a poster on the ongoing international Phase 3 PHOENIX trial (study A35-004, NCT05021536) of AMX0035 (sodium phenylbutyrate [PB] and taurursodiol [TURSO; also known as ursodoxicoltaurine]) in people living with amyotrophic lateral sclerosis (ALS) will be presented on Saturday, July 9, at the 17th International Congress on Neuromuscular Diseases (ICNMD 2022) in Brussels, Belgium.

Zsquare, a leading developer of high-performance, single-use endoscopes, announces that it received Food and Drug Administration 510K clearance to market its first product, the Zsquare ENT-Flex™ Rhinolaryngoscope.

The consistent Diamond-Blackfan Anemia Treatment business document showcases vital product developments and tracks recent acquisitions, mergers, and research in the Healthcare industry by the key players.

Brii Biosciences Limited (“Brii Bio” or the “Company”, stock code: 2137.HK) and TSB Therapeutics (Beijing) Co., Ltd. (“TSB Therapeutics”), today announced the commercial launch of the amubarvimab/romlusevimab combination, a long-acting COVID-19 neutralizing antibody therapy, in China.